Clinical Trials Directory

Trials / Sponsors / Taizhou Hanzhong biomedical co. LTD

Taizhou Hanzhong biomedical co. LTD

Industry · 11 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
UnknownA Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
Phase 32022-12-31
Not Yet RecruitingA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic C
Metastatic Colorectal Cancer
Phase 32022-12-20
UnknownStudy of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carc
Hepatocellular Carcinoma
Phase 22021-01-07
UnknownStudy of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Anaplastic Thyroid Cancer
Phase 22020-12-28
UnknownStudy of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Bladder Cancer
Phase 22020-09-25
UnknownHX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Ad
Nonsquamous Non-small Cell Lung Cancer
Phase 2 / Phase 32020-09-25
UnknownHX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Stomach Cancer
Phase 32020-09-16
UnknownA Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12019-09-05
UnknownA Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Triple-negative Breast Cancer
Phase 1 / Phase 22019-07-15
UnknownA Study of HX008 for the Treatment of Patients With Malignant Melanoma
Melanoma
Phase 22018-11-08
UnknownRecombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
Advanced Solid Tumor
Phase 22018-09-30